DOI Link
DOI
10.1016/s1474-4422(19)30485-5
Publication Date
2020-01-01
Publication Title
The Lancet Neurology
Volume
19
Issue
3
ISSN
1474-4422
Embargo Period
2020-07-28
First Page
214
Last Page
225
Recommended Citation
Chataway, J., De, A., Connick, P., Parker, R., Plantone, D., Doshi, A., John, N., Stutters, J., MacManus, D., Prados, C., Barkhof, F., Ourselin, S., Braisher, M., Ross, M., Cranswick, G., Pavitt, S., Giovannoni, G., Gandini, W., Hawkins, C., Sharrack, B., Bastow, R., Weir, C., Stallard, N., Chandran, S., Gandini, W., Williams, T., Beyene, T., Bassan, V., Zapata, A., Lyle, D., Williams, T., Braisher, M., Beyene, T., Bassan, V., Zapata, A., Chandran, S., Connick, P., Lyle, D., Cameron, J., Mollison, D., Colville, S., Dhillon, B., Weir, C., Parker, R., Ross, M., Cranswick, G., Giovannoni, G., Gnanapavan, S., Nicholas, R., Rashid, W., Aram, J., Ford, H., Overell, J., Young, C., Arndt, H., Duddy, M., Guadagno, J., Evangelou, N., Craner, M., Palace, J., Hobart, J., Sharrack, B., Paling, D., Hawkins, C., Kalra, S., McLean, B., Stallard, N., & Bastow, R. (2020) 'Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial', The Lancet Neurology, 19(3), pp. 214-225. Available at: 10.1016/s1474-4422(19)30485-5
